$CTOR
CITIUS ONCOLOGY, INC.

2022 Q4 Form 10-Q Financial Statement

#000149315222033847 Filed on November 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $138.1K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $138.1K $0.00
YoY Change
Operating Profit
YoY Change
Interest Expense $518.9K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $380.8K $0.00
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $380.8K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.04 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 8.941M shares 1.500M shares 1.500M shares
Diluted Shares Outstanding 1.500M shares 1.500M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $289.2K
YoY Change
Cash & Equivalents $289.2K
Short-Term Investments
Other Short-Term Assets $88.17K
YoY Change
Inventory
Prepaid Expenses $88.17K
Receivables
Other Receivables
Total Short-Term Assets $377.3K
YoY Change 198.48%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.81M
YoY Change
Other Assets $256.7K
YoY Change
Total Long-Term Assets $67.81M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $377.3K
Total Long-Term Assets $67.81M
Total Assets $68.19M $256.7K
YoY Change 53838.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $31.84K $73.69K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.84K $266.9K
YoY Change -76.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $31.84K $266.9K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $31.84K $266.9K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $345.3K -$10.11K
YoY Change -3514.08%
Common Stock $242.00 $173.00
YoY Change 39.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.5K -$10.11K -$10.11K
YoY Change
Total Liabilities & Shareholders Equity $68.19M $256.7K
YoY Change 53838.68%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2
OPERATING ACTIVITIES
Net Income $380.8K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$47.97K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$67.32M
YoY Change
Cash From Investing Activities -$67.32M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.66M
YoY Change
NET CHANGE
Cash From Operating Activities -47.97K 0.000
Cash From Investing Activities -67.32M
Cash From Financing Activities 67.66M
Net Change In Cash 289.2K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$47.97K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001851484
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 TENKU Formation Costs
FormationCosts
usd
CY2021Q3 TENKU Formation Costs
FormationCosts
usd
TENKU Formation Costs
FormationCosts
usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
us-gaap Net Income Loss
NetIncomeLoss
usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
us-gaap Net Income Loss
NetIncomeLoss
usd
TENKU Increase Decrease Formation And Organization Costs Paid By Related Parties
IncreaseDecreaseFormationAndOrganizationCostsPaidByRelatedParties
usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
TENKU Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41534
dei Entity Registrant Name
EntityRegistrantName
TenX Keane Acquisition
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Lexington Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2446
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10170
dei City Area Code
CityAreaCode
(347)
dei Local Phone Number
LocalPhoneNumber
627-0058
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8941000 shares
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
256745 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
126422 usd
CY2022Q3 us-gaap Assets
Assets
256745 usd
CY2021Q4 us-gaap Assets
Assets
126422 usd
CY2022Q3 TENKU Accrued Formation Costs Current
AccruedFormationCostsCurrent
73694 usd
CY2021Q4 TENKU Accrued Formation Costs Current
AccruedFormationCostsCurrent
5848 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
193164 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
130687 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
266858 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
136535 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2022Q3 TENKU Shareholder Receivable
ShareholderReceivable
-25000 usd
CY2021Q4 TENKU Shareholder Receivable
ShareholderReceivable
-25000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10113 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10113 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256745 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126422 usd
TENKU Formation Costs
FormationCosts
10113 usd
us-gaap Net Income Loss
NetIncomeLoss
-10113 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9389 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-9389 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-724 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-10113 usd
us-gaap Net Income Loss
NetIncomeLoss
-10113 usd
TENKU Increase Decrease Formation And Organization Costs Paid By Related Parties
IncreaseDecreaseFormationAndOrganizationCostsPaidByRelatedParties
10113 usd
TENKU Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
67846 usd
TENKU Deferred Offering Costs Included In Due To Related Party
DeferredOfferingCostsIncludedInDueToRelatedParty
62477 usd
TENKU Deferred Offering Costs Included In Due To Related Party
DeferredOfferingCostsIncludedInDueToRelatedParty
86913 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zSXdKT2Zqgy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_z5Ae0gxPLaAa">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zRSgMxTdLot8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zaTFjKGbyvuh">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zkkQPbbJSWFh" title="FDIC insured amount">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2021Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.00
CY2022Q3 us-gaap Share Price
SharePrice
10.00
CY2022Q3 TENKU Working Capital Loans
WorkingCapitalLoans
0 usd
CY2021Q4 TENKU Working Capital Loans
WorkingCapitalLoans
0 usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares

Files In Submission

Name View Source Status
0001493152-22-033847-index-headers.html Edgar Link pending
0001493152-22-033847-index.html Edgar Link pending
0001493152-22-033847.txt Edgar Link pending
0001493152-22-033847-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tenku-20220930.xsd Edgar Link pending
tenku-20220930_lab.xml Edgar Link unprocessable
tenku-20220930_cal.xml Edgar Link unprocessable
tenku-20220930_def.xml Edgar Link unprocessable
tenku-20220930_pre.xml Edgar Link unprocessable